| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| KIR2DL1 | Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $360.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Lirilumab | IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 | Phase 2 Clinical | Novo Nordisk A/S | Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |